Skip to content

Author

Ahmed Talkhan

We have 5 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

Abstract 16126: Antihypertensive Efficacy and Safety of Aldosterone Synthase (CYP11B2) Inhibitors: A GRADE-Guided Systematic Review and Meta-Analysis with Trial Sequential Analysis

Background: Persistent aldosterone-driven hypertension remains common despite established renin-angiotensin system blockade and mineralocorticoid receptor antagonism. Aldosterone synthase (CYP11B2) inhibition directly suppresses aldosterone biosynthesis, but its blood pressure (BP) effects across different agents an...

S. Ramadan, Amr M. Abou Elezz, Ahmed N. Mohamed et al. · 0 citations
Review Oct 2026

Efficacy and Safety of Recaticimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Low-density lipoprotein cholesterol (LDL-C) is the principal target for preventing atherosclerotic cardiovascular disease, yet many patients do not reach treatment goals with statins, and established proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies require injections every 2-4 weeks. Recaticimab is a hu...

Ahmed Talkhan, Amr M. Abou Elezz, N. Borham et al. · 0 citations
Review Sep 2026

Music as a Nonpharmacological Adjunct for Reducing Pain, Anxiety, and Physiological Stress During Cystoscopy: A Systematic Review and Meta-Analysis.

Music is a safe, inexpensive adjunct that effectively reduces pain, anxiety, and heart rate during cystoscopy and may enhance patient comfort and procedural tolerance.

Mohamed Abo Zeid, Michael Gerges, Kareem Khalefa et al. · 1 citation
Review Sep 2026

Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).

Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al. · 0 citations
Review Aug 2026

Non-invasive neuromodulation for LUTS in Parkinson's disease: a comprehensive systematic review and meta-analysis of tibial nerve stimulation with GRADE evaluation.

TNS improved urodynamic function in PD patients, but this objective improvement does not consistently translate to subjective symptom relief, highlighting the complexity of PD-related LUTS.

Mohamed F. Abo-elsoad, Ahmed W. Abbas, Amr M. Abou Elezz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.